$MBRX

Foster Jonathan P. purchased 293,333 shares of MBRX

Foster Jonathan P. (Chief Financial Officer) purchased 293,333 shares of Moleculin Biotech, Inc. (MBRX) on 2026-08-03.

Original reporting
SEC EDGAR · Foster Jonathan P.
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 3:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MBRX
Bullish
low confidence
Mentioned
$MBRX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MBRXBullishLow
01

Why it matters

The newest fact is the CFO’s open-market purchase of 293,333 shares on Aug. 3, with the filing submitted Aug. 5. The lack of disclosed price/value reduces tradable signal strength.

02

Market read

Traders may treat the filing as a mild bullish sentiment input, but it is unlikely to drive a major repricing without additional fundamental catalysts.

03

What to watch

The article does not state whether the purchase was part of any broader compensation or tax-related activity, and it provides no context on prior insider activity or company-specific news.

Relevance 4/10Novelty 5/10Timing: Form 4 filed Aug. 5, 2026, covering a purchase dated Aug. 3.

Background

This is an SEC Form 4 insider transaction disclosure for Moleculin Biotech, Inc. (MBRX).

Company-level read

Ticker impact

$MBRXBullishLow confidence
Context

Moleculin Biotech CFO Foster Jonathan P. bought 293,333 shares via an open-market Form 4 filed Aug. 5, 2026.

Expected impact

Low near-term impact; any effect is likely sentiment-driven and small.

Evidence & confidence

The filing is primary-source and company-specific, but the article provides no disclosed transaction price, no 10b5-1 plan, and no accompanying fundamental catalyst.

Market effects

Minimal; single-insider transaction does not materially change biotech sector fundamentals.

None indicated.

None indicated.

Counterpoint

Insider buying may be routine diversification or personal liquidity planning, and without the disclosed price it is hard to infer conviction.

Key entities

  • Moleculin Biotech, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Foster Jonathan P.

    Chief Financial Officer who purchased 293,333 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MBRXLow

Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout – Rapid completion of Part A enrollment underscores strong operational execution and investigator engagement in relapsed or refracto

$MBRXMedAI 8/10

Moleculin Advances Annamycin Following Peer-Reviewed Cardiac Safety Data

Moleculin Biotech (MBRX) published a peer-reviewed analysis in Frontiers in Cardiovascular Medicine, showing no cardiotoxicity in 90 patients treated with Annamycin across five trials. The study, evaluated by Cleveland Clinic, found no significant changes in left ventricular ejection fraction (LVEF) and no treatment-related cardiotoxicity. Annamycin is being evaluated in the MIRACLE trial for relapsed or refractory AML.

$MBRXMedAI 8/10

Moleculin Reports Cardiac Safety Findings For Annamycin In Pooled Analysis

Moleculin Biotech (MBRX) published cardiac safety findings for Annamycin, showing no evidence of cardiotoxicity in 90 patients across five trials. Mean LVEF remained stable, and no relationship was found between cumulative Annamycin exposure and LVEF changes. The analysis supports continued clinical evaluation of Annamycin, which is being studied in the MIRACLE trial for relapsed or refractory AML. MBRX stock closed at $0.60, up 6.12%, and is currently down 1.26% in pre-market trading.

$MBRXMedAI 8/10

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine – Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding tradition

$MBRXMedAI 8/10

Moleculin Biotech, Inc. (MBRX): Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Annamycin Turns “ Cold ” Pancreatic Tumors “ Hot ” in New Preclinical Data Presented at AACR Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin ’ s antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-medi